Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges

The occurrence and development of cancer are closely related to the immune escape of tumor cells and immune tolerance. Unlike previous surgical, chemotherapy, radiotherapy and targeted therapy, tumor immunotherapy is a therapeutic strategy that uses various means to stimulate and enhance the immune...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhitao Li, Guoqiang Sun, Guangshun Sun, Ye Cheng, Liangliang Wu, Qian Wang, Chengyu Lv, Yichan Zhou, Yongxiang Xia, Weiwei Tang
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	cancer PD-1/PD-L1 inhibitors drug combination therapy immunotherapy tumor microenvironment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/dbccacbd762c4d9bb560d433c84be82a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dbccacbd762c4d9bb560d433c84be82a
record_format	dspace
spelling	oai:doaj.org-article:dbccacbd762c4d9bb560d433c84be82a2021-11-17T05:21:58ZVarious Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges2234-943X10.3389/fonc.2021.771335https://doaj.org/article/dbccacbd762c4d9bb560d433c84be82a2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.771335/fullhttps://doaj.org/toc/2234-943XThe occurrence and development of cancer are closely related to the immune escape of tumor cells and immune tolerance. Unlike previous surgical, chemotherapy, radiotherapy and targeted therapy, tumor immunotherapy is a therapeutic strategy that uses various means to stimulate and enhance the immune function of the body, and ultimately achieves the goal of controlling tumor cells.With the in-depth understanding of tumor immune escape mechanism and tumor microenvironment, and the in-depth study of tumor immunotherapy, immune checkpoint inhibitors represented by Programmed Death 1/Programmed cell Death-Ligand 1(PD-1/PD-L1) inhibitors are becoming increasingly significant in cancer medication treatment. employ a variety of ways to avoid detection by the immune system, a single strategy is not more effective in overcoming tumor immune evasion and metastasis. Combining different immune agents or other drugs can effectively address situations where immunotherapy is not efficacious, thereby increasing the chances of success and alternative access to alternative immunotherapy. Immune combination therapies for cancer have become a hot topic in cancer treatment today. In this paper, several combination therapeutic modalities of PD1/PD-L1 inhibitors are systematically reviewed. Finally, an analysis and outlook are provided in the context of the recent advances in combination therapy with PD1/PD-L1 inhibitors and the pressing issues in this field.Zhitao LiGuoqiang SunGuangshun SunYe ChengLiangliang WuQian WangChengyu LvYichan ZhouYongxiang XiaWeiwei TangFrontiers Media S.A.articlecancerPD-1/PD-L1 inhibitorsdrug combination therapyimmunotherapytumor microenvironmentNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cancer PD-1/PD-L1 inhibitors drug combination therapy immunotherapy tumor microenvironment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	cancer PD-1/PD-L1 inhibitors drug combination therapy immunotherapy tumor microenvironment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Zhitao Li Guoqiang Sun Guangshun Sun Ye Cheng Liangliang Wu Qian Wang Chengyu Lv Yichan Zhou Yongxiang Xia Weiwei Tang Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
description	The occurrence and development of cancer are closely related to the immune escape of tumor cells and immune tolerance. Unlike previous surgical, chemotherapy, radiotherapy and targeted therapy, tumor immunotherapy is a therapeutic strategy that uses various means to stimulate and enhance the immune function of the body, and ultimately achieves the goal of controlling tumor cells.With the in-depth understanding of tumor immune escape mechanism and tumor microenvironment, and the in-depth study of tumor immunotherapy, immune checkpoint inhibitors represented by Programmed Death 1/Programmed cell Death-Ligand 1(PD-1/PD-L1) inhibitors are becoming increasingly significant in cancer medication treatment. employ a variety of ways to avoid detection by the immune system, a single strategy is not more effective in overcoming tumor immune evasion and metastasis. Combining different immune agents or other drugs can effectively address situations where immunotherapy is not efficacious, thereby increasing the chances of success and alternative access to alternative immunotherapy. Immune combination therapies for cancer have become a hot topic in cancer treatment today. In this paper, several combination therapeutic modalities of PD1/PD-L1 inhibitors are systematically reviewed. Finally, an analysis and outlook are provided in the context of the recent advances in combination therapy with PD1/PD-L1 inhibitors and the pressing issues in this field.
format	article
author	Zhitao Li Guoqiang Sun Guangshun Sun Ye Cheng Liangliang Wu Qian Wang Chengyu Lv Yichan Zhou Yongxiang Xia Weiwei Tang
author_facet	Zhitao Li Guoqiang Sun Guangshun Sun Ye Cheng Liangliang Wu Qian Wang Chengyu Lv Yichan Zhou Yongxiang Xia Weiwei Tang
author_sort	Zhitao Li
title	Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
title_short	Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
title_full	Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
title_fullStr	Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
title_full_unstemmed	Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
title_sort	various uses of pd1/pd-l1 inhibitor in oncology: opportunities and challenges
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/dbccacbd762c4d9bb560d433c84be82a
work_keys_str_mv	AT zhitaoli varioususesofpd1pdl1inhibitorinoncologyopportunitiesandchallenges AT guoqiangsun varioususesofpd1pdl1inhibitorinoncologyopportunitiesandchallenges AT guangshunsun varioususesofpd1pdl1inhibitorinoncologyopportunitiesandchallenges AT yecheng varioususesofpd1pdl1inhibitorinoncologyopportunitiesandchallenges AT liangliangwu varioususesofpd1pdl1inhibitorinoncologyopportunitiesandchallenges AT qianwang varioususesofpd1pdl1inhibitorinoncologyopportunitiesandchallenges AT chengyulv varioususesofpd1pdl1inhibitorinoncologyopportunitiesandchallenges AT yichanzhou varioususesofpd1pdl1inhibitorinoncologyopportunitiesandchallenges AT yongxiangxia varioususesofpd1pdl1inhibitorinoncologyopportunitiesandchallenges AT weiweitang varioususesofpd1pdl1inhibitorinoncologyopportunitiesandchallenges
_version_	1718425957466898432

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges

Ejemplares similares